Optimi Health is trading at $4.60 (+5.74%) after announcing a Health Canada-authorized Phase 2 trial for major depressive disorder.
- Up to 200 participants will enroll across Canadian sites in the first half of 2027; dosing should finish by year-end.
- Optimi said current cash can fund the trial; its scale, interim readouts and exclusive results ownership likely improved sentiment.
- Broader markets traded lower on inflation concerns; the release did not explicitly link this to trading.